BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’

Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to potentially introduce three new drugs to the market within the next 12 months | As BridgeBio ramps up for the launch of three new medicines and continues to channel resources into its soon-to-be-blockbuster in ATTR-CM, Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech.